
|Videos|October 15, 2017
Who Will Benefit from the Darunavir Single-Tablet Regimen for HIV?
Author(s)Contagion® Editorial Staff
Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.
Advertisement
Magda Opsomer, MD, director and clinical leader of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, Belgium, reveals who will benefit from the darunavir single-tablet HIV regimen.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement


























































































































































































































































































